Prominent roles of microRNA-142 in cancer

Pahlavan, Yasamin; Nasr, Mina Mohammadi; Abdolahinia, Elaheh Dalir; Pirdel, Zahra; Soofiyani, Saiedeh Razi; Siahpoush, Samaneh; Nejati, Kazem

doi:10.1016/j.prp.2020.153220

Cited by 28 publications

(17 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, low-risk single nucleotide polymorphisms, mutations of high-or moderate-risk genes e.g., BRCA1, BRCA2, TP53, ATM and CHEK are common factors contributing breast cancer (Cancer, 2019;Du et al, 2019). Indeed, breast cancer is an outcome of changes in cellular processes that promote cell proliferation and metastasis along with suppressing apoptosis (Javan et al, 2019;Pahlavan et al, 2020;Rasouli et al, 2020).…”

Section: Research Articlementioning

confidence: 99%

“…With the increasing number of cancer-related death worldwide, cancer has become one of the most important health issues and second principal causes of mortality estimated to reach for 606,520 people deaths in the United States in 2020 (national cancer institute) (Nejati-Koshki et al, 2014;Farajzadeh et al, 2018;Pahlavan et al, 2020). Among three prevalent neoplastic disease in women including colorectal cancer, lung cancer, breast cancer accounts for about 30% of all diagnosed cases and impacts over 1.5 million women each year (Lotfi-Attari et al, 2017;Jeddi et al, 2019;Nikmanesh et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anticancer Potential of Silibinin Loaded Polymeric Nanoparticles against Breast Cancer Cells: Insight into the Apoptotic Genes Targets

Pourgholi

Dadashpour

Mousapour

et al. 2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Silibinin (SIL) is a natural polyphenolic flavonoid with multiple biological and anti-cancer features. However, the complex hydrophobic nature and inadequate bioavailability of SIL hinder its efficiency at tumor sites. Investigating the possibility of an extensive strategy for better treatment of breast cancer, we carried out a comparative exploration of the inhibitory effect of SIL and SIL loaded PLGA-PEG nanoparticle (SIL-NPs) on the expression of the proapoptotic target genes, which is considered as an influential molecular target for treatment of breast cancer. The main diameter of SIL-NPs was 220 ± 6.37 and 150 ± 23.14 nm via DLS and FE-SEM respectively. Furthermore, the zeta potential of PLGA-PEG and SIL-NPs was -5.48±0.13 and -6.8±0.26 mV respectively. SIL encapsulation efficiency and drug release were determined by about 82.32 % by analyzing the calibration curve of SIL absorbance at 570 nm. Cytotoxicity of SIL and SIL-NPs was conducted by MTT assay after 24, 48, and 72 h of exposure times, and the gene expression levels of apoptotic genes, p53 and hTERT was measured by real-time PCR. Evaluation of drug toxicity revealed that SIL-NPs represents higher cytotoxic effects than pure SIL in a time and dose-dependent manner. Moreover, the results demonstrated that SIL-NPs could induce apoptosis in breast cancer cells by upregulation of caspase-3, caspase-7, p53 and Bax, along with Bcl-2, hTERT, survivin and Cyclin D1 down regulation. Our results indicated that PLGA-PEG can be used as stable carriers in nano-dimensions and SIL-NPs can be considered as a promising pharmacological agent for cancer therapy.

show abstract

Section: Research Articlementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Anticancer Potential of Silibinin Loaded Polymeric Nanoparticles against Breast Cancer Cells: Insight into the Apoptotic Genes Targets

Pourgholi

Dadashpour

Mousapour

et al. 2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…Moreover, blocking glutamine pathway can severely influence and suppress cell proliferation [ 9 ]. Recently, valuable studies and bioinformatics analysis demonstrated that some emerged microRNAs (miRNAs) can efficiently control glutamine metabolism by targeting critical enzymes, such as glutaminase (GLS), which can provide an opportunity for regulating cancer development [ 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

The expression of miR-513c and miR-3163 was downregulated in tumor tissues compared with normal adjacent tissue of patients with breast cancer

et al. 2021

View full text Add to dashboard Cite

Background Breast cancer (BC) is the most invasive cancer with different subtypes that its metabolism is unique compared with normal cells. Glutamine is considered critical nutrition that many cancer cells, particularly BC cells, are dependent on it for growth and proliferation. Therefore, targeting glutamine metabolism, especially enzymes that are related to this pathway, can be beneficial to design anti-cancer agents. Recent evidence has shown that microRNAs (miRNAs), with a short length and single-strand properties, play a prominent role in regulating the genes related to glutamine metabolism, which may control the development of cancer. Methods In silico analysis confirmed that miR-513c and miR-3163 might be involved in glutamine metabolism. The expression level of these two miRNAs was evaluated in eighty BC tissues and normal adjacent tissues. Furthermore, GSE38167, GSE38867, GSE42128, GSE45666, and GSE53179 were employed from gene expression omnibus (GEO). The Limma package was utilized to identify differentially expressed miRNAs (DEMs) of mentioned datasets to evaluate miR-513c and miR-3163 expression. Further, in silico analysis was utilized to predict the potential biological processes and molecular pathways of miR-513c and miR-3163, based on their target genes. Results In silico studies revealed top categories of biological processes and cellular pathways that might play a critical role in metabolism reprogramming and cancer development and were target genes for miR-513c and miR-3163. The current study showed that miR-513c (p value = 0.02062 and FC = − 2.3801) and miR-3163 (p value = 0.02034 and FC = − 2.3792) were downregulated in tumor tissues compared to normal adjacent tissues. The analysis of GEO microarray datasets showed that miR-513c was downregulated in GSE38167, GSE38867, GSE42128, GSE45666 and GSE53179, whereas there was a significant downregulation of miR-3163 in only two studies, including GSE38867 and GSE42128 that they were in accordance with our experimental results. Furthermore, the subgroup analysis did not show any substantial relationship between expression levels of these two miRNAs and factors such as age, family history of cancer, and abortion history. Conclusion MiR-513c and miR-3163 were downregulated in BC tissues, which might serve as tumor suppressors. They are suggested as potential therapeutic targets for patients with BC.

show abstract

“…Low-throughput genes, including NBS1, checkpoint kinase 2 (CHEK2), DNA repair protein Rad50 (RAD50), E-cadherin gene (CDH1), partner and localizer of BRCA2 (PALB2), and BRCA1-interacting protein 1 (BRIP1) that are often mutated in the global population mostly contribute to BC extension (11). Recent studies have also shown that miRNAs can regulate signaling pathways negatively or positively, thereby affecting tumorigenesis and various aspects of cancer progression, particularly BC (12)(13)(14). Cancer-causing driver mutations confer selective clonal growth advantage and oncogenic potential to cells.…”

Section: Contextmentioning

confidence: 99%

Prominent Prognostic Factors in Aggressive Breast Cancer: A Review

et al. 2021

Self Cite

View full text Add to dashboard Cite

Context: Breast cancer (BC) is the most common cancer in women worldwide. Hereditary susceptibility created by mutations in autosomal dominant genes is responsible for 5 to 10% of all BC cases in women. Recent studies have identified genes associated with increased risk for aggressive BC, providing the basis for better risk management. Evidence Acquisition: The latest information in National Center for Biotechnology Information (NCBI), Google Scholar, ScienceDirect, and Scopus were the main databases for finding articles. A combination of keywords of ‘metastasis’, ‘invasion’, ‘aggressive breast cancer’, ‘prognostic factor’, ‘mutation’, and ‘cancer treatment’ was searched in the databases to identify related articles. Titles and abstracts of the articles were studied to choose the right articles. Results: Mutations in breast cancer type 1 susceptibility protein (BRCA1) and breast cancer type 2 susceptibility protein (BRCA2) genes are two central players related to the high risk of BC. Mutation in tumor protein p53 (TP53) is another important mutation that leads to triple-negative BC. Although the majority of BC types are not associated with high-throughput mutant genes such as BRCA1, BRCA2, and TP53, they are associated with low-throughput genes, including DNA repair protein Rad50 (RAD50), Nijmegen breakage syndrome gene (NBS1), checkpoint kinase 2 (CHEK2), BRCA1-interacting protein 1 (BRIP1), E-cadherin gene (CDH1) and PALB2, UCHL1, aldehydedehydrogenase1A3 (ALDH1A3), androgen receptor (AR), 5-bisphosphate 3-kinase (PIK3CA), phosphatidylinositol-4, and luminal gene expression that are generally mutated in the global population. High tumor mutational burden (TMB) was associated with improved progression-free survival. Conclusions: The lymph node status, early tumor size, ER, PR, human epidermal growth factor receptor-2 (HER2), and Ki-67 are conventional prognostic factors for BC. However, these factors cannot exactly predict the aggressive behavior of BC. Hence, in this review, we discussed new prognostic factors of aggressive BCs that are useful for the treatment of patients with BC.

show abstract

Prominent roles of microRNA-142 in cancer

Cited by 28 publications

References 64 publications

Anticancer Potential of Silibinin Loaded Polymeric Nanoparticles against Breast Cancer Cells: Insight into the Apoptotic Genes Targets

Anticancer Potential of Silibinin Loaded Polymeric Nanoparticles against Breast Cancer Cells: Insight into the Apoptotic Genes Targets

The expression of miR-513c and miR-3163 was downregulated in tumor tissues compared with normal adjacent tissue of patients with breast cancer

Prominent Prognostic Factors in Aggressive Breast Cancer: A Review

Contact Info

Product

Resources

About